Gemeinsamkeiten und Unterschiede der primären Radiotherapie beim lokalisierten und lokal fortgeschrittenen Prostatakarzinom in der Schweiz : Eine Analyse der der Behandlungskonzepte Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland : A survey on patterns of practice.
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_90BE0A0F0301
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Gemeinsamkeiten und Unterschiede der primären Radiotherapie beim lokalisierten und lokal fortgeschrittenen Prostatakarzinom in der Schweiz : Eine Analyse der der Behandlungskonzepte Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland : A survey on patterns of practice.
Périodique
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al]
ISSN
1439-099X (Electronic)
ISSN-L
0179-7158
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
191
Numéro
10
Pages
778-786
Langue
anglais
Notes
Publication types: ARTICLE
Publication Status: ppublish
Publication Status: ppublish
Résumé
INTRODUCTION: External beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT), is an established treatment option for nonmetastatic prostate cancer. Despite high-level evidence from several randomized trials, risk group stratification and treatment recommendations vary due to contradictory or inconclusive data, particularly with regard to EBRT dose prescription and ADT duration. Our aim was to investigate current patterns of practice in primary EBRT for prostate cancer in Switzerland.
MATERIALS AND METHODS: Treatment recommendations on EBRT and ADT for localized and locally advanced prostate cancer were collected from 23 Swiss radiation oncology centers. Written recommendations were converted into center-specific decision trees, and analyzed for consensus and differences using a dedicated software tool. Additionally, specific radiotherapy planning and delivery techniques from the participating centers were assessed.
RESULTS: The most commonly prescribed radiation dose was 78 Gy (range 70-80 Gy) across all risk groups. ADT was recommended for intermediate-risk patients for 6 months in over 80 % of the centers, and for high-risk patients for 2 or 3 years in over 90 % of centers. For recommendations on combined EBRT and ADT treatment, consensus levels did not exceed 39 % in any clinical scenario. Arc-based intensity-modulated radiotherapy (IMRT) is implemented for routine prostate cancer radiotherapy by 96 % of the centers.
CONCLUSION: Among Swiss radiation oncology centers, considerable ranges of radiotherapy dose and ADT duration are routinely offered for localized and locally advanced prostate cancer. In the vast majority of cases, doses and durations are within the range of those described in current evidence-based guidelines.
MATERIALS AND METHODS: Treatment recommendations on EBRT and ADT for localized and locally advanced prostate cancer were collected from 23 Swiss radiation oncology centers. Written recommendations were converted into center-specific decision trees, and analyzed for consensus and differences using a dedicated software tool. Additionally, specific radiotherapy planning and delivery techniques from the participating centers were assessed.
RESULTS: The most commonly prescribed radiation dose was 78 Gy (range 70-80 Gy) across all risk groups. ADT was recommended for intermediate-risk patients for 6 months in over 80 % of the centers, and for high-risk patients for 2 or 3 years in over 90 % of centers. For recommendations on combined EBRT and ADT treatment, consensus levels did not exceed 39 % in any clinical scenario. Arc-based intensity-modulated radiotherapy (IMRT) is implemented for routine prostate cancer radiotherapy by 96 % of the centers.
CONCLUSION: Among Swiss radiation oncology centers, considerable ranges of radiotherapy dose and ADT duration are routinely offered for localized and locally advanced prostate cancer. In the vast majority of cases, doses and durations are within the range of those described in current evidence-based guidelines.
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/07/2015 11:28
Dernière modification de la notice
29/03/2023 7:13